Health Desk- 12 August, 2020: China-based Oryx Biotech's announces to invest $300 million to set up a plasma fractionation plant in Bangladesh.
The company Tuesday inked the tripartite agreement with Summit Technopolis, a company of Summit Group, and the Bangladesh Hi-Tech Park Authority (BHTPA) for the country's first biotech investment at a programme at the ICT Division in Dhaka.
Oryx will set up the plasma fractionation plant on 25 acres of land and building provided by Summit Technopolis to produce plasma derivatives, also known as life-saving therapeutics and other related products.
The plasma fractionation project will open a new horizon in Bangladesh's development, said Muhammed Aziz Khan, founder chairman of Summit Group.
Oryx will now invest $10 million, said Zunaid Ahmed Palak, state minister for ICT, in a press release.